# Rapalogix Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rapalogix-health

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.rapalogix.com/
- Total disclosed funding: $19M
- Latest round: Series A (Jun 22, 2026)
- Investors on record: 2

## About

Based in the US, Rapalogix Health, Inc. delivers advanced dermatology therapeutics and skincare solutions, utilizing mTOR science to combat skin aging and disease effectively. The company is committed to restoring skin health and resilience.Rapalogix Health, Inc. focuses on innovative dermatological solutions, having been founded in 2024 by Rahul Mehta, PhD (Co-Founder & CEO), Doris Day, MD (Co-Founder), Brent Saunders (Co-Founder), and James Peyer, PhD (Co-Founder and Board Chair) in the US. The company raised USD 19.10 million in its Series A funding round on June 23, 2026, co-led by GordonMD Global Investments and Woodline Partners. The founder's experience or any previous ventures are not disclosed.

Rapalogix specializes in innovative dermatology therapeutics and skincare solutions, leveraging advanced mTOR science to address fundamental biological causes of skin aging and disease. Core offerings include therapeutic products for dermatologic conditions linked to TORC1 dysregulation and professional skincare products designed to enhance skin balance and vitality. The company serves dermatologists, skincare professionals, and end consumers, focusing primarily on North America and Europe.

Rapalogix generates revenue through a blend of direct-to-consumer sales and partnerships with healthcare professionals and retailers. Its proprietary skincare products are tailored to address specific skin health issues, available individually or as part of curated skincare regimens. Pricing reflects the premium nature of the products, emphasizing their scientific foundation and efficacy while fostering long-term relationships with clients through education and clinical support.

In June 2026, Rapalogix Health, Inc. raised USD 19 million in Series A funding to enhance its service and business development. The company aims to expand its product line by designing new dermatology therapeutics and skincare solutions, although specific release dates are not provided. Geographically, Rapalogix targets expansion into additional regions in North America and Europe to broaden its market reach.

## Funding rounds

- Series A, Jun 22, 2026, $19M — Woodline Partners, GordonMD Global Investments

## Investors

- Woodline Partners — Series A
- GordonMD Global Investments (https://capitalatlas.ai/funds/gordonmd-global-investments) — Series A